

At'ty Docket: 1544.03

IN THE SPECIFICATION:

Please amend the specification as described in the attached specification amendment. No new matter was added in the amendment.

IN THE DRAWINGS:

Please amend FIG. 2 as described in the attached marked up drawings. Annotated marked up drawings and replacement sheets of drawings are attached.

No new matter was added in the amendment.

REMARKS

Claims 1, 4 and 6 were rejected as being indefinite for the use of indefinite terms or expressions.

In response, claims 1, 4 and 6 were amended to clarify the meanings of the terms and expressions. Also the corresponding parts of the specification were amended, and FIG. 2 was amended to incorporate more clear illustration. The amendments are supported by page 8 of the original specification and obvious to any person skilled in the art to which the invention pertains.

In the amendment, the symbol for the transfer vector was corrected to "pBacPAK8", and the symbol for help vector was corrected to "BacPAK6". phLf-8 corresponds to lactoferrin gene inserted into pT7T3 vector. pT7T3 vector is a basic cloning vector and an existing recombinant plasmid. FIG. 2 illustrates "phLf-8" in detail.

Claim 6 was rejected as being anticipated by Arnold et al. (Infection and Immunity 28, 893-898 (1980)).

In response, claim 6 was amended to change "E.coli" to "E.coli 300". E.coli 300 is pathogenic bacteria, and is different from the non-pathogenic E.coli strain that is disclosed in the cited reference. E.coli 300 in claim 6 is pathogenic bacteria, while E.coli in the cited reference is non-pathogenic and means normal bacteria within the intestines.

Att'y Docket: 1544.03

**CONCLUSION**


The applicant believes that the rejections were obviated by the amendment of specification, claims, and drawings, and the application is now in condition for allowance: therefore, reexamination, reconsideration and allowance of the claims are respectively requested. If there is any additional comments or requirements from the examination, the applicant asks for a non-final office action.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication, or credit any over-payment to Deposit Account No. 16-0310.

Very truly yours,

Park & Sutton LLP

Dated: 5/20, 2004

By: 

John K. Park

Regis. No. 37,904

3255 Wilshire Blvd., Suite 1110

Los Angeles, California 90010

Tel: (213) 389-3777